Want to see NL:LKFT full AI Analyst Report?
Lakefront Biotherapeutics NV (LKFT) Financial Statements
Lakefront Biotherapeutics NV Financial Overview
Lakefront Biotherapeutics NV's market cap is currently $1.91B. The company's EPS TTM is $7.39; its P/E ratio is 3.91; Lakefront Biotherapeutics NV is estimated to report earnings on November 12, 2026, and the estimated EPS forecast is $-0.72. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 1.11B | $ 275.65M | $ 239.72M | $ 505.28M | $ 484.85M |
| Gross Profit | $ 1.03B | $ 240.79M | $ 203.74M | $ 493.20M | $ 483.22M |
| Operating Income | $ 469.66M | $ -188.34M | $ -88.26M | $ -267.52M | $ -165.60M |
| EBITDA | $ 521.51M | $ 43.33M | $ 51.04M | $ 3.87M | $ -100.93M |
| Net Income | $ 320.88M | $ 74.08M | $ 211.70M | $ -217.99M | $ -125.42M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 3.00B | $ 3.12B | $ 3.68B | $ 4.09B | $ 4.70B |
| Total Assets | $ 3.41B | $ 4.14B | $ 4.36B | $ 4.73B | $ 5.19B |
| Total Debt | $ 6.92M | $ 11.72M | $ 9.60M | $ 21.90M | $ 26.86M |
| Net Debt | $ -80.95M | $ -52.52M | $ -157.21M | $ -486.22M | $ -2.21B |
| Total Liabilities | $ 170.65M | $ 1.24B | $ 1.56B | $ 2.21B | $ 2.55B |
| Stockholders' Equity | $ 3.24B | $ 2.90B | $ 2.80B | $ 2.53B | $ 2.64B |
| Cash Flow | |||||
| Free Cash Flow | $ -210.71M | $ -402.14M | $ -425.24M | $ -537.49M | $ -561.71M |
| Operating Cash Flow | $ -197.01M | $ -320.03M | $ -405.97M | $ -500.54M | $ -503.83M |
| Investing Cash Flow | $ 228.37M | $ 220.60M | $ 71.19M | $ -1.25B | $ 541.24M |
| Financing Cash Flow | $ -3.27M | $ -4.92M | $ -5.00M | $ -1.49M | $ -3.88M |
Currency in EUR
